Similar articles

• Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease.

  Regueiro M, Valentine J, Plevy S, Fleisher MR, Lichtenstein GR. Regueiro M, et al. Am J Gastroenterol. 2003 Aug;98(8):1821-6. doi: 10.1111/j.1572-0241.2003.07581.x. Am J Gastroenterol. 2003. PMID: 12907338
• [Pyoderma gangrenosum--a less well known ulcerous skin disease].

  Kostiainen M, Snellman E, Vaalasti A, Rantanen T, Reunala T. Kostiainen M, et al. Duodecim. 2002;118(10):1033-7. Duodecim. 2002. PMID: 12237998 Finnish. No abstract available.
• Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum.

  Triantafillidis JK, Cheracakis P, Sklavaina M, Apostolopoulou K. Triantafillidis JK, et al. Scand J Gastroenterol. 2002 Jul;37(7):863-5. Scand J Gastroenterol. 2002. PMID: 12190104
• Infliximab for the treatment of disseminated pyoderma gangrenosum associated with ulcerative colitis. Case report and literature review.

  Juillerat P, Christen-Zäch S, Troillet FX, Gallot-Lavallée S, Pannizzon RG, Michetti P. Juillerat P, et al. Dermatology. 2007;215(3):245-51. doi: 10.1159/000106584. Dermatology. 2007. PMID: 17823524 Review.
• Severe recalcitrant pyoderma gangrenosum treated with infliximab.

  Kaur MR, Lewis HM. Kaur MR, et al. Br J Dermatol. 2005 Sep;153(3):689-91. doi: 10.1111/j.1365-2133.2005.06812.x. Br J Dermatol. 2005. PMID: 16120178 Review. No abstract available.